Dapirolizumab pegol | UCB
UCB's Global Corporate Website

Dapirolizumab pegol

Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available)
Systemic Lupus Erythematosus Phase 2 SL0023
Completed
NCT02804763
2015-004457-40
LINK
Furie, R. et al. Ann Rheum Dis 2019; 78 (Suppl. 2), p. 775
Systemic Lupus Erythematosus Phase 3 SL0043
Ongoing
NCT04294667
2019-003406-27
Systemic Lupus Erythematosus Phase 3 SL0046
Ongoing
NCT04976322
2019-003409-83